Background: Selectively targeting dopamine receptors has been a persistent challenge in the last years for the development of new treatments to combat the large variety of diseases evolving these receptors. Although, several drugs have been successfully brought to market, the subtype-specific binding mode on a molecular basis has not been fully elucidated.Methods: Homology modeling and molecular dynamics were applied to construct robust conformational models of all dopamine receptor subtypes (D1-like and D2like receptors). Fifteen structurally diverse ligands were docked to these models. Contacts at the binding pocket were fully described in order to reveal new structural findings responsible for DR sub-type specificity.
Results:We showed that the number of conformations for a receptor:ligand complex was associated to unspecific interactions > 2.5 Å and hydrophobic contacts, while the decoys binding energy was influenced by specific electrostatic interactions. Known residues such as 3.32Asp, the serine microdomain and the aromatic microdomain were found interacting in a variety of modes (HB, SB, πstacking). Purposed TM2-TM3-TM7 microdomain was found to form a hydrophobic network involving Orthosteric Binding Pocket (OBP) and Secondary Binding Pocket (SBP). T-stacking interactions revealed as especially relevant for some large ligands such as apomorphine, risperidone or aripiprazole.Conclusions: This in silico approach was successful in showing known receptorligand interactions as well as in determining unique combinations of interactions, key for the design of more specific ligands.The strive for finding new and effective therapeutics led to a growing interest in the use of Computer Aided Drug Design (CADD). Originally developed for High-Throughput Screening (HTS) of compound libraries, the use of CADD nowadays plays an important role in drug discovery [24]. Modeling three-dimensional (3D) target proteins help to visualize, analyse and optimize known ligands and discover new lead compounds [25]. The CADD pipeline can be classified in two general categories: structure-based and ligand-based, dependent on the available information about the topic of investigation [25]. A structure-based CADD is used when the target, e.g. a receptor, is known and so compound libraries can be screened to find suitable structures for the target. Usually protein-ligand docking studies are performed or ligands are designed de novo and are then used for compound library screening to test possible lead structures experimentally. Vice-versa, a ligand-based CAAD procedure is used when ligand structure information is provided to create pharmacophore models and to perform virtual screening [24]. All in all, CADD faces the challenges of identifying novel targets and their ligands, for example to treat common and rare diseases [26].
AimModeling G protein-coupled receptors (GPCRs) remains challenging due to the complex structure of these membrane proteins and the lack of structural information about the desired receptor to target, however CADD m...